Board-Grade Revenue Truth
for Healthtech
Most healthtech companies reporting strong ARR are measuring the wrong things.
I install revenue truth systems for PE- and VC-backed healthtech companies that need commercial clarity before their next board meeting, raise, or renewal.
The Problem
The Metrics Look Fine.
That's the Problem.
Your board sees 110% NRR. Your forecast is within 8% of plan. CAC payback looks reasonable.
What the board doesn't see:
- The NRR includes a contractual price escalator – not expansion.
- The forecast is accurate because your CRO moved the goal post in week 10.
- The CAC payback excludes the 14 weeks of dev time required to ship the integration your sales team promised.
These aren't edge cases. They're the standard operating mode of healthtech companies between Series A and exit. The metrics aren't lying – they were never designed to tell the truth.
Structural Observations
The Three Revenue Fictions
No. 1 Attribution Fiction
The Pattern
A care management company secures a multi-year enterprise contract. Program ROI is internally modeled, board-approved, and embedded in the investor narrative. At renewal, the payer's actuarial team runs their own study. The savings attribution doesn't hold. The contract isn't renewed.
The Structural Cause
In reimbursement-dependent healthcare, program ROI is not a finance problem. It's an actuarial problem. The companies that survive renewal are the ones that engaged the payer's actuarial team during the buy cycle – not after go-live.
The Signal
You've never had a named conversation with the actuary at your largest payer.
No. 2 Acquisition Economics Mirage
The Pattern
ARR is growing at 109%. CAC looks efficient. What's not in the board deck: the sales team is closing on customization promises the dev team has to fulfill post-sale. Implementations are slipping. A competitor shows up at the same conference twelve months later with a nearly identical product. Several customers are already evaluating alternatives.
The Structural Cause
CAC that excludes delivery cost isn't CAC – it's a down payment on churn. When the sales motion depends on promises that require custom engineering to fulfill, the real payback period is measured in customer satisfaction surveys, not months.
The Signal
Your expansion attach rate is under 20% and your best account managers spend most of their time managing expectations, not growing accounts.
No. 3 Segment Mirage
The Pattern
The board narrative says "strong enterprise traction." The actual data: one segment – provider groups under 50 physicians – drives 71% of new logos. That segment has a 22-month CAC payback and 74% gross retention. The "enterprise" segment has three logos, two of which haven't expanded in 18 months.
The Structural Cause
Blended metrics hide segment economics. When ICP definitions shift quarterly to flatter underperforming cohorts, no one has a clean view of which customers actually produce the economics the business model requires.
The Signal
Your CAC, NRR, and GRR are reported as company-wide averages, not by segment.
How I Work
The Revenue Truth System
This is not a GTM audit. It's not a pipeline review. It's a structured installation of the measurement architecture and commercial processes that make revenue defensible to a board, an acquirer, or a payer's actuarial team.
Three components. Ninety days. Delivered as an interim CRO engagement.
Component 1: Actuarial Defensibility
For payer-facing, VBC, care management, and bundled payment companies.
The question isn't whether your program works. The question is whether your program's economic value can survive independent actuarial review at renewal. Most can't – not because the program doesn't work, but because the attribution model, comparison cohort, and measurement methodology were never designed to hold up under scrutiny.
I align your clinical outcomes data with an actuarially defensible measurement architecture before the payer's team builds their own model without you.
Component 2: Acquisition Economics Reconstruction
For any healthtech company where CAC payback, LTV:CAC, or NRR are board-level KPIs.
I rebuild the segment-level economics from the ground up – real CAC (including delivery cost), real LTV (based on cohort depth, not extrapolation), and real NRR (expansion only, no escalators).
The output is a 12-metric board-grade scorecard that doesn't require a footnote to defend.
Component 3: GTM Systemization
For companies transitioning from founder-led or relationship-driven sales to a repeatable, institutionally credible pipeline.
Stage weights that reflect actual close probability. Forecast models tied to behavior, not hope. ICP definitions graded by segment economics, not intuition. Sales capacity allocation based on real ramp curves, not headcount plans.
The output is a commercial motion that can be explained to a board in five minutes and stress-tested by a PE firm's operating partner in thirty.
The Artifacts
Free, No Gate, High Signal
The frameworks below are the instruments I use in every engagement. Download them. Use them. If something feels uncomfortably accurate, that's the point.
Board-Grade Revenue Truth – Healthtech Edition
The 12-metric table specifically calibrated for PE- and VC-backed healthtech companies. Includes definitions, Pass/Watch/Fail bands, and the common lie embedded in each metric. One page. Designed to be shown to a board.
Module 1: Reimbursement + Actuarial Defensibility
For payer-facing companies. The four questions your actuarial engagement strategy must answer before you sign an enterprise contract. The three signals that your program ROI won't survive independent review. The engagement model that works.
Module 2: Revenue Truth Self-Diagnostic
Twelve questions. Score yourself Pass, Watch, or Fail on each metric cluster. If you score two or more Fails, you have a board conversation coming that you're not currently prepared for. No interaction required – just honest answers.
Module 3: Healthtech Revenue Benchmark Index
Market benchmark ranges for all 12 metrics, sourced from public healthtech and SaaS data. Pre-populated. Replace the benchmarks with your actuals. See where you stand. Designed for VC/PE platform contacts to forward to portfolio companies as a self-diagnostic.
The Operator
I've spent fifteen years at the intersection of healthcare technology and enterprise revenue – managing a $90M+ payer book at Ontrak, closing top-three deals in company history at LexisNexis/Milliman, and co-founding a fintech platform that exited to KeepTrue.
What I've learned from that time: the companies that struggle commercially aren't struggling because they have bad products. They're struggling because their revenue metrics are built to report progress, not reveal truth. The board sees what the model is designed to show.
Freeboard Advisory exists to fix that – as an interim CRO embedded in your company for ninety days, building the measurement architecture and commercial motion that holds up under the scrutiny that every PE-backed or VC-funded healthtech company eventually faces.
I work with companies in the $3M–$20M ARR range. Engagements begin with a 30-minute revenue briefing – no pitch, no scope document, just an honest look at where your metrics are likely obscuring commercial risk.
Ready to see what the board will see before they do?
The 30-minute revenue briefing is free. It's a structured conversation – not a sales call. We look at three metrics together. You leave knowing whether you have a board conversation coming that your current reporting won't survive.
Book a Revenue Briefing